WellsSA, AsaSL, DralleH, et al.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 2015; 25(6):567–610; doi: 10.1089/THY.2014.0335
2.
BihanH, MuratA, FysekidisM, et al.The clinical spectrum of RET proto-oncogene mutations in codon 790. Eur J Endocrinol, 2013; 169(3):271–276; doi: 10.1530/EJE-13-0050
3.
EliseiR, CosciB, RomeiC, et al.Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab, 2008; 93(3):682–687; doi: 10.1210/JC.2007-1714
4.
LombardoF, BaudinE, ChiefariE, et al.Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab, 2002; 87(4):1674–1680; doi: 10.1210/JCEM.87.4.8403
5.
MarshDJ, AndrewSD, EngC, et al.Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res, 1996; 56(6):1241–1243.
6.
MathiesenJS, NielsenSG, Rasmussen ÅK, et al. Variability in medullary thyroid carcinoma in RET L790F carriers: A case comparison study of index patients. Front Endocrinol (Lausanne), 2020; 11; doi: 10.3389/FENDO.2020.00251
